Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

References

• Pauly N, Ehmann S, Ricciardi E, Ataseven B, Bommert M, Heitz F, et al. Low-grade serous tumors: are we making progress? Curr Oncol Rep. 2020;22:8. doi:10.1007/s11912-020-0872-5
   PubMed Web of Science ®Google Scholar
• Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014;24:S9–S13. doi:10.1097/IGC.0000000000000257
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy. Int J Gynecol Cancer. 2019. doi:10.1136/ijgc-2019-000832
   PubMed Web of Science ®Google Scholar
• Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: a review. Gynecol Oncol. 2016;143:433–8. doi:10.1016/j.ygyno.2016.08.320
   PubMed Web of Science ®Google Scholar
• Turashvili G, Grisham RN, Chiang S, DeLair DF, Park KJ, Soslow RA, et al. BRAF(V)(600E) mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary. Histopathology. 2018;73:438–43. doi:10.1111/his.13651
   PubMed Web of Science ®Google Scholar
• Campos MP, Cohen M, Von Euw E, Velculescu V, Kujak JL, Conklin D, et al. BRAF mutations occur infrequently in ovarian cancer but suggest responsiveness to BRAF and MEK inhibition. JCO Precis Oncol. 2018. doi:10.1200/PO.18.00025
   PubMed Web of Science ®Google Scholar
• Moujaber T, Etemadmoghadam D, Kennedy C, Chiew YE, Balleine RL, Saunders C, et al.; Australian Ovarian Cancer Study. BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition. JCO Precis Oncol. 2018;2:1–9. doi:10.1200/PO.17.00221
   PubMed Web of Science ®Google Scholar
• Gershenson D, Miller A, Brady W, Paul J, Carty K, Rodgers W, et al. Randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. Ann Oncol. 2019;30:v897–934. doi:10.1093/annonc/mdz394.058
   PubMed Web of Science ®Google Scholar
• Grisham B, Monk S, Banerjee R, et al. 1 MILO/ENGOT-OV11: phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. Int J Gynecol Cancer. 2019;29:A1.1–A1.
   Web of Science ®Google Scholar
• Combe P, Chauvenet L, Lefrere-Belda MA, Blons H, Rousseau C, Oudard S, et al. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation. Invest New Drugs. 2015;33:1267–70. doi:10.1007/s10637-015-0297-4
   PubMed Web of Science ®Google Scholar
• Mendivil AA, Tung PK, Bohart R, Bechtol K, Goldstein BH. Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation. Gynecol Oncol Rep. 2018;26:41–4. doi:10.1016/j.gore.2018.09.002
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626–36. doi:10.1056/NEJMoa1904059
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315–27. doi:10.1016/S1470-2045(18)30497-2
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603–15. doi:10.1016/S1470-2045(18)30142-6
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100–3. doi:10.1038/nature10868
   PubMed Web of Science ®Google Scholar
• Moens LN, Falk-Sorqvist E, Ljungstrom V, Mattsson J, Sundström M, La Fleur L, et al. HaloPlex targeted resequencing for mutation detection in clinical formalin-fixed, paraffin-embedded tumor samples. J Mol Diagn. 2015;17:729–39. doi:10.1016/j.jmoldx.2015.06.009
   PubMed Web of Science ®Google Scholar
• Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, et al. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Res. 2014;24:468–74. doi:10.1097/CMR.0000000000000110
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. doi:10.1056/NEJMoa1412690
   PubMed Web of Science ®Google Scholar
• Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496–504. doi:10.1097/00000478-200404000-00009
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S. Therapeutic approach to low-grade serous ovarian carcinoma: state of art and perspectives of clinical research. Cancers (Basel). 2020;12:1336. doi:10.3390/cancers12051336
   Web of Science ®Google Scholar